Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-07
1998-01-13
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514213, 514410, 540576, 546 61, 548420, A61K 3158, C07D22118
Patent
active
057080011
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/US93/12419 filed Dec. 17, 1993 which claims priority from U.S. Ser. No. 08/080,665 filed 18 Jun. 1992 now abandoned, and U.S. Ser. No. 07/993,930 filed 18 Dec. 1992 now abandoned.
The present invention relates to certain substituted 17.beta.-substituted -6-azaandrost-4-en-3-ones and their use as 5.alpha.-testosterone reductase inhibitors.
BACKGROUND OF THE INVENTION
Androgens are responsible for many physiological functions in both males and females. Androgen action is mediated by specific intracellular hormone receptors expressed in androgen responsive cells. Testosterone, the major circulating androgen, is secreted by Leydig cells of the testes under the stimulation of pituitary-derived luteinizing hormone (LH). However, reduction of the 4,5 double bond of testosterone to dihydrotestosterone (DHT) is required in some target tissues, such as prostate and skin, for androgen action. Steroid 5.alpha.-reductases in target tissues catalyze conversion of testosterone to DHT in an NADPH dependent fashion as shown in Scheme A. ##STR2##
The requirement for DHT to act as an agonist in these target tissues has been highlighted by studies of steroid 5.alpha.-reductase deficient individuals who have vestigial prostate glands and do not suffer from acne vulgaris or male pattern baldness (see McGinley, J. et al., The New England J. of Medicine, 300, 1233 (1979)). Thus, inhibition of the conversion of testosterone to DHT in these target tissues is anticipated to be useful in the treatment of a variety of androgen responsive diseases, e.g., benign prostatic hyperplasia, prostate cancer, ache, male pattern baldness, and hirsutism.
Additionally, it has recently been discovered that two isozymes of 5.alpha.-reductase exist in humans which differ in their tissue distribution, affinity for testosterone, pH profile and sensitivity to inhibitors (see Russell, D. W. et al., J. Clin. Invest., 89, 293 (1992); Russell, D. W. et al., Nature, 354, 159 (1991)). The steroid 5.alpha.-reductase deficient individuals studied by Imperato-McGinley are deficient in the type 2, 5.alpha.-reductase enzyme (Russell, D. W. et al., J. Clin. Invest., 90, 799 (1992); Russell, D. W. et al., New England J. Med., 327, 1216 (1992)), which is the predominant isozyme present in the prostate, while the type 1 isozyme is predominant in the skin. The relative value of isozyme specific and dual inhibitors of the two isozymes of 5.alpha.-reductase will depend upon the type of disease treated (benign prostatic hyperplasia, prostate cancer, acne, male pattern baldness, or hirsutism) as well as the stage of the disease (prevention versus treatment) and the anticipated side-effects in the intended patients (for example treatment of acne vulgaris in pubescent males).
Because of their valuable therapeutic potential, testosterone inhibitors"! have been the subject of active research worldwide. For example, see: Hsia, S. and Voight, W., J. Invest. Derm., 62, 224 (1973); Robaire, B. et al., J. Steroid Biochem., 8, 307 (1977); Petrow, V. et al., Steroids, 38, 121 (1981); Liang, T. et al., J. Steroid Biochem., 19, 385 (1983); Holt, D. et al., J. Med. Chem., 33, 937 (1990); U.S. Pat. No. 4,377,584, U.S. Pat. No. 4,760,071 and U.S. Pat. No. 5,017,568. Two particularly promising 5.alpha.-reductase inhibitors are MK-906 (Merck), known by the generic name, finasteride, and marketed under the trademark, Proscar; and SKF-105657 (SmithKline Beecham), shown in Scheme B. ##STR3##
The potent inhibition of bovine adrenal and porcine granulosa cell 3.beta.-hydroxy-.DELTA..sup.5 -steroid dehydrogenase/3-keto-.DELTA..sup.5 -steroid isomerase (3.beta.HSD) by the 4-azasteroid derivative, 4-MA, shown in Scheme C and not by the drug finasteride (Tan, C. H.; Fong, C. Y.; Chan, W. K. Biochem. Biophys. Res. Comm., 144, 166 (1987) and Brandt, M.; Levy, M. A. Biochemistry, 28, 140 (1989)) along with the critical role of 3.beta.HSD in steroid biosynthesis (Potts, G. O. et al., Steroids, 32, 257 (1978)), suggests that optimal inhibitors of type 1 and 2 5.alpha.-
REFERENCES:
patent: 4377584 (1983-03-01), Rasmusson et al.
patent: 5084574 (1992-01-01), Bhattacharya et al.
patent: 5302589 (1994-04-01), Frye et al.
patent: 5438061 (1995-08-01), Bergman et al.
Jacobs, T.L. et al, J. Am. Chem. Soc. 1960, pp. 4033-4039.
J.P. Kutney, et al., "Synthesis of Ring A-Oxygenated 6-AZA-Steroids," Tetrahedron, 24, No. 2, pp. 845-857, Jan. 1968.
D. Vinod, et al., "Resolution of Conflicting Migratory Reports in Ring Expansion of 3-Keto Steroids to Oxygen and Nitrogen," Canadian J. of Chem., 58, No. 23, pp. 2666-2678, Dec. 1980.
Andrews Robert Carl
Cribbs Cynthia Markert
Frye Stephen Vernon
Haffner Curt Dale
Maloney Patrick Reed
Brink Robert H.
Dahlen Garth M.
Glaxo Wellcome Inc.
Ivy C. Warren
LandOfFree
Substituted 6-azaandrostenones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 6-azaandrostenones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 6-azaandrostenones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-326508